Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733533 | 0.83 | LMNA (0.52) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6737762 | 0.81 | ALDH1A1 (0.60) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6733860 | 0.77 | ELANE (0.56) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL7685083 | 0.77 | ELANE (0.56) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6738470 | 0.77 | ALDH1A1 (0.54) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6735158 | 0.77 | ALDH1A1 (0.54) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6740943 | 0.77 | ALDH1A1 (0.54) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6740952 | 0.77 | ALDH1A1 (0.54) | LMNAMAPTALDH1A1L3MBTL1TSHR | |
| SCHEMBL6971418 | 0.76 | LMNA (0.54) | LMNAMAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL6740194 | 0.76 | ALDH1A1 (0.60) | LMNAMAPTALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6686357-B1 | BENZIMIDAZOLO-PIPERIDINE COMPOUND | PFIZER, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6509464-B1 | 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation | PFIZER INC | 2003-01-21 | — | — | US | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| EP-1098894-B1 | FKBP INHIBITORS | PFIZER LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| CN-1315951-A | FKBP inhibitors | PFIZER LTD (US) | 2001-10-03 | — | — | CN | disclosed |
| US-6166011-A | FKBP inhibitors | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | FKBP1A, FKBP4, FKBP1B | LMNA 4322/4885MAPT 11/4885ALDH1A1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.